NCT05737784View on ClinicalTrials.gov

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2027

Conditions
SCN2A-DEEEpilepsy
Interventions
DRUG

PRAX-222 - Initial Dose

PRAX-222

DRUG

PRAX-222 - Initial Ascending Doses

Ascending doses of PRAX-222

DRUG

PRAX-222 - Optional Ascending Doses

Escalation of PRAX-222 dose(s)

DRUG

PRAX-222 - Fixed Doses

Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222

PROCEDURE

Placebo

Placebo procedure

Trial Locations (3)

38103

COMPLETED

Le Bonheur Childrens Hospital, Memphis

90035-003

RECRUITING

Hospital de Clinicas de Porto Alegre, Porto Alegre

05403-010

RECRUITING

Praxis Research Site, São Paulo

Sponsors
All Listed Sponsors
lead

Praxis Precision Medicines

INDUSTRY

NCT05737784 - A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy | Biotech Hunter | Biotech Hunter